125 related articles for article (PubMed ID: 29390274)
21. The genetic tumor background is an important determinant for heterogeneous MYCN-amplified neuroblastoma.
Bogen D; Brunner C; Walder D; Ziegler A; Abbasi R; Ladenstein RL; Noguera R; Martinsson T; Amann G; Schilling FH; Ussowicz M; Benesch M; Ambros PF; Ambros IM
Int J Cancer; 2016 Jul; 139(1):153-63. PubMed ID: 26910568
[TBL] [Abstract][Full Text] [Related]
22. [Abnormality of anaplastic lymphoma kinase gene and its expression in pediatric neuroblastoma].
Chen S; Zhou C; Ma X; Gong L
Zhonghua Bing Li Xue Za Zhi; 2014 Aug; 43(8):541-5. PubMed ID: 25346125
[TBL] [Abstract][Full Text] [Related]
23. Peripheral neuroblastic tumors with genotype-phenotype discordance: a report from the Children's Oncology Group and the International Neuroblastoma Pathology Committee.
Suganuma R; Wang LL; Sano H; Naranjo A; London WB; Seeger RC; Hogarty MD; Gastier-Foster JM; Look AT; Park JR; Maris JM; Cohn SL; Amann G; Beiske K; Cullinane CJ; d'Amore ES; Gambini C; Jarzembowski JA; Joshi VV; Navarro S; Peuchmaur M; Shimada H
Pediatr Blood Cancer; 2013 Mar; 60(3):363-70. PubMed ID: 22744966
[TBL] [Abstract][Full Text] [Related]
24. Metachronous Medulloblastoma in a Child With Successfully Treated Neuroblastoma: Case Report and Novel Findings of DNA Sequencing.
Eterovic AK; Maher OM; Chandra J; Chen K; Huse J; Zaky W
J Natl Compr Canc Netw; 2018 Jun; 16(6):683-691. PubMed ID: 29891519
[TBL] [Abstract][Full Text] [Related]
25. What is the benefit of aggressive chemotherapy for advanced neuroblastoma with N-myc amplification? A report from the Japanese Study Group for the Treatment of Advanced Neuroblastoma.
Suita S; Zaizen Y; Kaneko M; Uchino J; Takeda T; Iwafuchi M; Utsumi J; Takahashi H; Yokoyama J; Nishihira H
J Pediatr Surg; 1994 Jun; 29(6):746-50. PubMed ID: 8078011
[TBL] [Abstract][Full Text] [Related]
26. Activating mutations in ALK provide a therapeutic target in neuroblastoma.
George RE; Sanda T; Hanna M; Fröhling S; Luther W; Zhang J; Ahn Y; Zhou W; London WB; McGrady P; Xue L; Zozulya S; Gregor VE; Webb TR; Gray NS; Gilliland DG; Diller L; Greulich H; Morris SW; Meyerson M; Look AT
Nature; 2008 Oct; 455(7215):975-8. PubMed ID: 18923525
[TBL] [Abstract][Full Text] [Related]
27. Beyond sequence variation: assessment of copy number variation in adult glioblastoma through targeted tumor somatic profiling.
McNulty SN; Cottrell CE; Vigh-Conrad KA; Carter JH; Heusel JW; Ansstas G; Dahiya S
Hum Pathol; 2019 Apr; 86():170-181. PubMed ID: 30594748
[TBL] [Abstract][Full Text] [Related]
28. Correlation between ARID1B gene mutation (p.A460, p.V215G) and prognosis of high-risk refractory neuroblastoma.
Zhang Y; Chen M; Huang D; Gu H; Yi Y; Meng X
Cell Biol Int; 2023 Jul; 47(7):1222-1228. PubMed ID: 36883912
[TBL] [Abstract][Full Text] [Related]
29. Genetic staging of unresectable or metastatic neuroblastoma in infants: a Pediatric Oncology Group study.
Bowman LC; Castleberry RP; Cantor A; Joshi V; Cohn SL; Smith EI; Yu A; Brodeur GM; Hayes FA; Look AT
J Natl Cancer Inst; 1997 Mar; 89(5):373-80. PubMed ID: 9060959
[TBL] [Abstract][Full Text] [Related]
30. Familial neuroblastoma - different histological manifestations in a family with three affected individuals.
Zimling ZG; Rechnitzer C; Rasmussen M; Petersen BL
APMIS; 2004 Feb; 112(2):153-8. PubMed ID: 15056233
[TBL] [Abstract][Full Text] [Related]
31. Alternative pathways of MYCN gene copy number increase in primary neuroblastoma tumors.
Valent A; Guillaud-Bataille M; Farra C; Lozach F; Spengler B; Terrier-Lacombe MJ; Valteau-Couanet D; Danglot G; Lenoir GM; Brison O; Bénard J; Bernheim A
Cancer Genet Cytogenet; 2004 Aug; 153(1):10-5. PubMed ID: 15325088
[TBL] [Abstract][Full Text] [Related]
32. [Survival of patients with primary central nervous system diffuse large B-cell lymphoma: impact of gene aberrations and protein overexpression of bcl-2 and C-MYC, and selection of chemotherapy regimens].
Yin WJ; Zhu X; Yang HY; Sun WY; Wu MJ
Zhonghua Bing Li Xue Za Zhi; 2018 Jan; 47(1):32-38. PubMed ID: 29325248
[No Abstract] [Full Text] [Related]
33. Improving Mutation Screening in Patients with Colorectal Cancer Predisposition Using Next-Generation Sequencing.
Rey JM; Ducros V; Pujol P; Wang Q; Buisine MP; Aissaoui H; Maudelonde T; Olschwang S
J Mol Diagn; 2017 Jul; 19(4):589-601. PubMed ID: 28502729
[TBL] [Abstract][Full Text] [Related]
34. Evaluating the Calling Performance of a Rare Disease NGS Panel for Single Nucleotide and Copy Number Variants.
Cacheiro P; Ordóñez-Ugalde A; Quintáns B; Piñeiro-Hermida S; Amigo J; García-Murias M; Pascual-Pascual SI; Grandas F; Arpa J; Carracedo A; Sobrido MJ
Mol Diagn Ther; 2017 Jun; 21(3):303-313. PubMed ID: 28290094
[TBL] [Abstract][Full Text] [Related]
35. Next-generation assessment of human epidermal growth factor receptor 2 gene (ERBB2) amplification status in invasive breast carcinoma: a focus on Group 4 by use of the 2018 American Society of Clinical Oncology/College of American Pathologists HER2 testing guideline.
Hoda RS; Bowman AS; Zehir A; Razavi P; Brogi E; Ladanyi M; Arcila ME; Wen HY; Ross DS
Histopathology; 2021 Mar; 78(4):498-507. PubMed ID: 32841416
[TBL] [Abstract][Full Text] [Related]
36. Image-Guided Biopsy for Relapsed Neuroblastoma: Focus on Safety, Adequacy for Genetic Sequencing, and Correlation of Tumor Cell Percent With Quantitative Lesion MIBG Uptake.
Samoyedny A; Srinivasan A; States L; Mosse YP; Alai E; Pawel B; Pogoriler J; Shellikeri S; Vatsky S; Acord M; Escobar F; Edgar JC; Maris JM; Cahill AM
JCO Precis Oncol; 2021; 5():. PubMed ID: 34250393
[TBL] [Abstract][Full Text] [Related]
37. Identification of Germline Mismatch Repair Gene Mutations in Lung Cancer Patients With Paired Tumor-Normal Next Generation Sequencing: A Retrospective Study.
Sun S; Liu Y; Eisfeld AK; Zhen F; Jin S; Gao W; Yu T; Chen L; Wang W; Chen W; Yuan M; Chen R; He K; Guo R
Front Oncol; 2019; 9():550. PubMed ID: 31297337
[No Abstract] [Full Text] [Related]
38. Concomitant p53 mutation and MYCN amplification in neuroblastoma.
Manhani R; Cristofani LM; Odone Filho V; Bendit I
Med Pediatr Oncol; 1997 Sep; 29(3):206-7. PubMed ID: 9212845
[TBL] [Abstract][Full Text] [Related]
39. Pan-neuroblastoma analysis reveals age- and signature-associated driver alterations.
Brady SW; Liu Y; Ma X; Gout AM; Hagiwara K; Zhou X; Wang J; Macias M; Chen X; Easton J; Mulder HL; Rusch M; Wang L; Nakitandwe J; Lei S; Davis EM; Naranjo A; Cheng C; Maris JM; Downing JR; Cheung NV; Hogarty MD; Dyer MA; Zhang J
Nat Commun; 2020 Oct; 11(1):5183. PubMed ID: 33056981
[TBL] [Abstract][Full Text] [Related]
40. Identification of candidate genes involved in neuroblastoma progression by combining genomic and expression microarrays with survival data.
Łastowska M; Viprey V; Santibanez-Koref M; Wappler I; Peters H; Cullinane C; Roberts P; Hall AG; Tweddle DA; Pearson AD; Lewis I; Burchill SA; Jackson MS
Oncogene; 2007 Nov; 26(53):7432-44. PubMed ID: 17533364
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
